RxDoctor Payments DataLook up a doctor →

Donald Haas, MD

Advanced Heart Failure and Transplant Cardiology · Abington, PANPI 1205876406

Payments from drug & device makers

$1,442,935in general payments, 2019–2025

Across 277 payments — averaging $5209.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$438K
  • AstraZeneca$262K
  • Abbott$243K
  • American Regent$204K
  • Nuwellis, Inc.$73K
  • Procyrion, Inc.$50K
  • plus $172K from 14 others

What the payments were for

  • Consulting fees$14,67840%
  • Speaking & faculty fees$20,16955%
  • Travel & lodging$690%
  • Food & beverage$1,9815%
  • Education$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,442,935 in reported general payments places this provider in the 95th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.

See all advanced heart failure and transplant cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$90,873
Medicare patients
229
Services billed
877

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis249$5,803,275
WainuaEplontersen Sodium11$462,197
CamzyosMavacamten22$183,305
OpsumitMacitentan13$166,974
EntrestoSacubitril/Valsartan88$115,969
Bosentan13$66,870
EliquisApixaban34$55,523
JardianceEmpagliflozin48$52,421
Bisoprolol Fumarate59$3,314
Digoxin52$2,831
Torsemide107$2,471
Metoprolol Succinate119$2,223
Valsartan51$2,044
Isosorbide Dinitrate24$1,857
Bumetanide27$1,713

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$19,026$5,858,797283 claims
AstraZenecaWainua$262,025$462,19711 claims
E.r. Squibb & Sons, L.L.C.Camzyos$41,777$183,30522 claims
NovartisEntresto$438,422$115,96988 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 96 advanced heart failure and transplant cardiology providers in Pennsylvania.

Other advanced heart failure and transplant cardiology in Abington

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →